POPULAR CABG Trial Summary: Ticagrelor in CABG

popular cabg trial ticagrelor

2020 POPULAR CABG TRIAL Effect of adding ticagrelor to standard aspirin on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting double-blind, placebo-controlled, multicenter, randomized controlled trial M Objective: To assess whether ticagrelor added to standard aspirin Dimproves SVG patency among patients undergoing coronary artery bypass grafting (CABG) 499 Inclusion criteria: Patients ≥ 21 years who underwent planned patients coronary artery bypass graft surgery with > 1 saphenous vein grafts (SVGs) VS Ticagrelor group (n=249) Placebo group (n=247) PRIMARY OUTCOME 9.6 SVG occlusion at 1 year % 10.1 OR 0.87; 95% CI, 0.49 to 1.55; P=0.64 SECONDARY OUTCOMES 12.9 SVG failure at 1 year % HR 1.04; 95% CI, 0.63 to 1.69 13.0 2.8 All-cause mortality % 0 Conclusion: The addition of ticagrelor to standard aspirin did not reduce SVG occlusion at 1 year after CABG LM Willemsen et al. Circulation. 2020;142:1799-1807

Comments are closed.